Evidence map›Paper›PMID 30402771›Full record

ArticleApplied microbiology and biotechnology2019

Prospects for the use of spherical gold nanoparticles in immunization.

Sergey A Staroverov, Alexei A Volkov, Pavel V Mezhenny, Ivan Yu Domnitsky, Alexander S Fomin, Sergey V Kozlov, Lev A Dykman, Olga I Guliy

Open access · bronzeAbstract read
In one paragraph

Article in Applied microbiology and biotechnology, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers.

0numbers the graph read from it
0cells of the map it votes in
15citing papers in PubMed
1.5field-weighted citation impact, top 17% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

15 citing papers in PubMed, 28 citations in OpenAlex.

  1. Review
  2. Article
  3. Review
  4. Antiviral potential of nanoparticles for the treatment of Coronavirus infections.Journal of trace elements in medicine and biology : organ of the Society for Minerals and Trace Elements (GMS) · 2022
    Review
  5. Review
  6. Article
  7. Article
  8. Nanotherapeutics for treating coronavirus diseases.Journal of drug delivery science and technology · 2021
    Review
  9. Article
  10. Review
  11. Review
  12. Review
  13. Review
  14. Review
  15. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 2 institutions in 1 country.

Sergey A StaroverovInstitute of Biochemistry and Physiology of Plants and Microorganisms, Russian Academy of Sciences, Saratov, Russian Federation.
Alexei A VolkovSaratov State Vavilov Agrarian University, Saratov, Russian Federation.
Pavel V MezhennySaratov State Vavilov Agrarian University, Saratov, Russian Federation.
Ivan Yu DomnitskySaratov State Vavilov Agrarian University, Saratov, Russian Federation.
Alexander S FominInstitute of Biochemistry and Physiology of Plants and Microorganisms, Russian Academy of Sciences, Saratov, Russian Federation.
Sergey V KozlovSaratov State Vavilov Agrarian University, Saratov, Russian Federation.
Lev A DykmanInstitute of Biochemistry and Physiology of Plants and Microorganisms, Russian Academy of Sciences, Saratov, Russian Federation.
Olga I GuliyInstitute of Biochemistry and Physiology of Plants and Microorganisms, Russian Academy of Sciences, Saratov, Russian Federation. guliy_olga@mail.ru.
Saratov State Agrarian University named after N.I .Vavilov · RUInstitute of Biochemistry and Physiology of Plants and Microorganisms · RU

Funding

Russian Science Foundation 18-14-00016
6 · The paper itself

Abstract

Recent years have seen extremely fast development of new viral nanovaccines and diagnostic agents using nanostructures prepared by biological and chemical synthesis. We used spherical gold nanoparticles (average diameter, 15 nm) as a platform for the antigen for swine transmissible gastroenteritis virus (TGEV). The literature data demonstrate that immunization of animals with the TGEV antigen coupled to gold nanoparticles (GNPs) not only activates antigen-presenting cells but also increases the proliferative activity of splenic lymphoid (antibody-forming) cells. The contents of γ-IFN, IL-1β, and IL-6 in animals immunized with GNP-antigen conjugates were found to be higher than those in intact animals or in animals given the antigen alone. The increased concentration of IL-1β in the immunized animals directly correlated with the activity of macrophages and stimulated B cells, which produce this cytokine when activated. The increased concentration of IL-6 indicates that the injected preparations are stimulatory to cellular immunity. Immunization with the TGEV antigen conjugated to GNPs as a carrier activates the respiratory activity of lymphoid cells and peritoneal macrophages, which is directly related to their transforming activity and to the activation of antibody generation. Furthermore, the use of this conjugate allows marked improvement of the structure of the animals' immune organs and restores the morphological-functional state of these organs. The microanatomical changes (increased number of follicles) indicate the activation of the B-dependent zone of the spleen and, consequently, the development of a humoral-type immunological reaction. The degradative processes observed in the animals immunized with TGEV antigen alone are evidence of weak resistance to pathogen attack. These results can be used to develop vaccines against this infection by employing TGEV antigen coupled to gold nanoparticles as a carrier.

Indexed as

AnimalsAntigens, ViralDrug CarriersGoldGuinea PigsImmunizationInterferon-gammaMacrophages, PeritonealMaleMetal NanoparticlesSpleenTransmissible gastroenteritis virusAntigens, ViralDrug CarriersGoldInterferon-gammaGold nanoparticleGuinea pigImmune system organsImmunizationNanovaccineSwine transmissible gastroenteritisVirus antigen

Identifiers

PMID30402771
PMCPMC7080143
OpenAlexW2899893936

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.